A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Purpose

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Conditions

  • Chronic Lymphocytic Leukemia
  • Lymphoma, Small Lymphocytic

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020

Exclusion Criteria

  • This is not applicable to this study

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Pirtobrutinib (Arm A) 		Participants receive pirtobrutinib orally
  • Drug: Pirtobrutinib
    Administered orally
    Other names:
    • LY3527727
Experimental
Idelalisib (Arm B) 		Participants receive idelalisib orally
  • Drug: Idelalisib
    Administered orally

Recruiting Locations

Mitchell Cancer Institute
Mobile, Alabama 36693
Contact:
334-660-5108

Cancer Specialists, LLC
Jacksonville, Florida 32256
Contact:
904-538-4488

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York 10065-6007
Contact:
646-608-4273

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com